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Abstract
Cardiovascular disease (CVD) is responsible for 30% of deaths worldwide and 
is the leading cause of premature mortality in patients with diabetes mellitus (DM). 
One of the main contributors to the increased atherothrombotic risk in DM patients 
relates to their pro- inflammatory and prothrombotic status that involves abnormal-
ities in endothelial and vascular smooth muscle cells, in platelet function and the 
coagulation cascade. The characteristics of CAD in diabetic patients is distinctive 
and infers an increased risk. Likewise, CAD in diabetics is characterised by being 
diffuse, affecting the left main stem more frequently, involving multiple vessels, 
and also affecting the distal coronary tree. Percutaneous coronary intervention in 
diabetics has been shown to have less favourable long-term clinical outcomes, com-
pared to non-diabetics. With the advent of improved stent designs and antiplatelet 
drugs; the percutaneous coronary intervention (PCI) results have improved in the 
diabetic population. However, one of the main determinants of poorer outcomes 
in DM is the progression of atherosclerosis, which is more pronounced in diabetics 
and remains the primary cause of cardiac events at one year follow up after percuta-
neous revascularisation. Whilst new generation of drug-eluting stents has narrowed 
the gap between surgery and PCI in diabetic patients, coronary artery bypass 
grafting (CABG) remains the gold standard in diabetics with diffuse multivessel 
coronary artery disease.
Keywords: diabetes mellitus, coronary artery bypass grafting, percutaneous 
coronary intervention, antiplatelet drugs, drug-eluting stents
1. Introduction
The prevalence of diabetes mellitus has increased exponentially, from 108 million 
in 1980 to 422 million worldwide in 2014 [1].Cardiovascular diseases (CVDs) con-
stitute the number one cause of mortality globally, representing 30% of all global 
deaths [2]. Cardiovascular disease is the leading cause of morbidity and premature 
mortality in patients with diabetes mellitus (DM) [3–6]. A meta-analysis of 102 
prospective studies (The Emerging Risk Factor Collaboration) showed that DM 
in general, confers an increased risk for developing vascular disease compared to 
non-diabetic patients [7]. DM increases the risk of coronary heart disease, stroke, 
and peripheral arterial disease by between two and four-fold. The increased risk is 
independent of, and additional to other cardiovascular risk factors [7–10].
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It has been reported that between 20 and 30% of patients with coronary artery 
disease have known DM, and up to 70% have newly detected DM or impaired 
glucose tolerance [11]. Importantly, the risk of myocardial infarction (MI) is three 
to five times higher in type 2 DM. A diabetic patient with no history of MI has 
the same long-term risk as a non-DM subject with a past history of MI [12]. For 
these reasons, DM is considered to be a “coronary heart disease equivalent” [13]. 
The anatomical pattern of coronary artery disease (CAD) in patients with DM 
influences the prognosis [11]. The extension of CAD in diabetic patients exhibits 
distinctive characteristics that infer an increased risk. Likewise, CAD in diabetics 
is characterised by being diffuse, affecting the left main stem more frequently, 
involving multiple vessels, and also affecting the distal coronary tree [14]. CAD 
typically progresses more rapidly in diabetic compared with non-diabetics [15]. 
Furthermore, patients with DM have more associated comorbidities, such as 
peripheral artery disease, cerebrovascular disease or chronic kidney disease, which 
influence outcomes after coronary revascularisation [11].
The indications for myocardial revascularisation, for both symptomatic and 
prognostic reasons, were the same in patients with or without DM [16]. The ana-
tomical pattern in which diabetes affects patients, combined with an increased 
risk of stent failure (restenosis and stent thrombosis), in conjunction with the 
“Prothrombotic State” that characterised these patients, resulted in poorer out-
comes following revascularisation in general. However, it is particularly evident 
following percutaneous revascularisation.
Three randomised clinical trials compared percutaneous coronary intervention 
(PCI) vs. coronary artery bypass graft surgery in patients with DM, using mainly 
first-generation drug-eluting stents (DES) [11]. With this in mind, safety concerns 
following PCI have surfaced, specifically with the use of first-generation DES, as 
diabetes has emerged as an independent predictor of stent thrombosis (ST) [17]. 
Recently, new generation DES platforms were designed and have demonstrated 
improved safety outcomes, compared to the first generation. Thus, coronary artery 
bypass grafting has been the revascularisation treatment recommended in diabetics 
with multivessel disease.
Although the advent of drug-eluting stents has narrowed the gap between 
surgery and the percutaneous treatment, the former remains the gold standard in 
diabetics with diffuse coronary artery disease.
One of the main determinants of poor outcomes in DM is the progression of 
atherosclerosis, which is more pronounced in diabetics and remains the main cause 
of cardiac events at one year follow up, after percutaneous revascularisation. This 
review focuses on all the aforementioned issues, which affect diabetic patients, as 
well as any updates to the current evidence regarding the different modalities of 
revascularisation in this special population.
2. Vascular abnormalities and atherothrombotic risk in diabetic patients
DM is linked to an increased atherothrombotic risk. In fact, diabetics with 
coronary artery disease suffer a higher rate of recurrence following their index MI 
[18]. Atherothrombotic disease is accelerated in subjects with both type 1 and type 
2 diabetes, with diverse underlying mechanisms, despite the common characteristic 
of hyperglycaemia. The main feature of type 2 DM is insulin resistance, which 
precedes the development of hyperglycaemia [19]. Contrastingly, in type 1 diabetes, 
hyperglycaemia is the dominant feature with insulin resistance appearing at later 
stages, in patients who develop renal disease [20].
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One of the main contributors to the increased atherothrombotic risk in DM 
patients relates to their pro- inflammatory and prothrombotic status that involves 
abnormalities in endothelial and vascular smooth muscle cells, in platelet function 
and the coagulation cascade. Endothelial dysfunction in diabetics is character-
ised by a decrease in nitric oxide (NO), and also by an increase in the synthesis 
of vasoconstrictor prostanoids and endothelin [21]. Hyperglycaemia decreases 
endothelium-derived NO via multiple mechanisms, including the intracellular 
production of advanced glycation end-products (AGEs) and free radical formation 
[22, 23]. Furthermore, hyperglycaemia also produces an increase in the concentra-
tion in plasma of vasoconstrictors, such as endothelin, which is related to both the 
incidence of inflammation and smooth-muscle contraction and growth. Other 
metabolic disorders known to occur in diabetes including an increase in the circu-
lating levels of free fatty acid, an increase in the production of free radicals or an 
exacerbation of dyslipidaemia, may also impair the endothelial function [24–26]. 
On the other hand, hyperinsulinemia [ 27] also plays an important role in the patho-
physiological mechanisms that may contribute towards vascular disease in diabetic 
patients. The concentration in plasma of vasoconstrictors, such as endothelin, 
increases after administration of insulin to healthy subjects and patients with type 2 
diabetes [28–31]. This phenomenon may be related to both the incidence of inflam-
mation and smooth-muscle contraction and growth. In addition, hyperinsulinemia 
is a potent mitogen for restenosis, as it stimulates the proliferation and migration 
of smooth cells [32]. Previous studies have demonstrated that hyperinsulinaemia 
enhances the secretion of insulin during the oral glucose tolerance test, and is a 
predictor of restenosis after balloon angioplasty and stent implantation [33–35].
Platelets are also affected in diabetic patients. Both insulin resistance and hyper-
glycaemia contribute to a prothrombotic state by exerting several salient effects on 
both coagulation and platelet function. The effects of insulin resistance on platelet 
function is related to intra-cytosolic calcium levels, a mediator of platelet activa-
tion. Whilst insulin decreases the intra-cellular concentration of calcium in platelets 
from insulin-sensitive subjects in vivo and in vitro, it appears to increase the intra-
platelet calcium concentrations in the insulin-resistant state, promoting platelet 
aggregation and activation [36]. Platelets obtained from diabetic subjects showed 
both increased adhesiveness and an exaggerated aggregation following activation 
[24]. In addition, reduced responsiveness of diabetic patients to antiplatelet therapy 
has been documented [14]. The overall picture of platelet abnormalities in DM 
results in the hypersensitivity of diabetic platelets to agonists. In fact, platelets in 
diabetic subjects appear to be in an activated state even in the absence of vascular 
injury, and they respond more frequently even to sub threshold stimuli. It has been 
shown that there is greater expression of the fibrinogen-binding glycoprotein IIb/
IIIa receptor, which constitutes the final common pathway of platelet activation 
and allows for cross-linking of individual platelets by fibrinogen molecules and 
formation of thrombus [15]. Finally, there is also impairment of the coagulation 
cascade. Insulin resistance gives rise to increased levels of the fibrinolytic inhibi-
tor Plasminogen Activator Inhibitor-1 (PAI-1), and hyperglycaemia induces the 
enhancement of thromboxane A2 production and an increase in factor VII and 
anti-thrombin III production [24–26].
The alteration in platelet function is especially relevant in diabetics patients 
treated percutaneously, as it may affect the response to antiplatelet treatment. 
Although, clopidogrel response variability is a multifactorial process, the mecha-
nisms above explain why dual antiplatelet regimen with ASA and clopidogrel 
presents important limitations in diabetic patients. The main mechanisms in this 
patient cohort that explain poor response to dual antiplatelet therapy in diabetes 
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mellitus are antiplatelet resistance and clopidogrel response variability. Variability 
in antiplatelet effects following clopidogrel therapy is present in both the acute and 
the chronic phases of therapy [37]. Of note, diabetics requiring insulin are those 
who persist with the highest platelet reactivity, despite dual antiplatelet therapy 
[37]. This antiplatelet variability has clinical implications, such as increased rates 
of coronary stent thrombosis and recurrent ischaemic events after PCI in poor 
clopidogrel responders. Among the clinical factors involved in clopidogrel vari-
ability, diabetes mellitus has been associated with a greater prevalence of poor 
responsiveness [38]. Overall, the persistence of elevated platelet reactivity and 
reduced response to aspirin and clopidogrel therapy enhances the atherothrombotic 
risk of DM patients. Multiple causes have been implicated in these observations. 
Poor glycaemic control is an important cause of increased platelet reactivity. 
Hyperglycaemia leads to non-enzymatic glycation of platelet glycoproteins, causing 
changes in their structure and conformation, as well as alterations of membrane 
lipid dynamics. This may explain why platelet reactivity can be reduced with tight 
control of glucose levels [39].
The introduction of new regimens and antiplatelet agents may improve and 
overcome the variability in the response to clopidogrel. The P2Y12 inhibitors, 
with a more uniform and potent effect, have recently been evaluated. Prasugrel 
is a P2Y12 inhibitor of the third generation, with more potent and less variable 
antiplatelet effects compared to clopidogrel [ 40]. The TRITON-TIMI 38 (TRial to 
Assess Improvement in Therapeutic Outcomes by Optimising Platelet InhibitioN 
with Prasugrel-Thrombolysis in Myocardial Infarction) trial showed significantly 
reduced rates of ischaemic events, including stent thrombosis, in patients pre-
senting with acute coronary syndromes undergoing PCI treated with prasugrel 
compared to clopidogrel [ 41]. In the subgroup analyses of diabetes population 
(n = 3146) the greatest risk reduction (rate of primary endpoint, defined as death 
from cardiovascular causes, non-fatal MI or non-fatal stroke) was observed in 
12.2% of the diabetics treated with prasugrel vs. 17.0% in diabetic patients on clopi-
dogrel with 30% relative risk reduction. Importantly, prasugrel was not associated 
with an increased risk of major bleedings compared to clopidogrel in these patients 
[42]. The functional impact of prasugrel versus clopidogrel, specifically in diabetic 
patients, was evaluated in the OPTIMUS-3 study. In this prospective, randomised, 
double-blind, crossover study, the standard-dose prasugrel was associated with 
greater platelet inhibition and better response profiles during both the loading and 
maintenance periods, when compared with double-dose clopidogrel [43].
On the other hand, ticagrelor, has a faster onset and offset of action and achieves 
higher inhibition of platelet aggregation compared to clopidogrel. In the RESPOND 
trial [44] Ticagrelor therapy overcomes nonresponsiveness to clopidogrel, and 
its antiplatelet effect is the same in responders and non-responders. The phase 
III Study of Platelet Inhibition and Patient Outcomes (PLATO) trial randomised 
acute coronary syndrome patients (n = 18,624) to receive either ticagrelor (180 mg 
loading dose followed by 90 mg twice daily) or clopidogrel (300–600 mg load-
ing dose followed by 75 mg daily). In a predefined subgroup analysis of diabetic 
patients (n = 4662) there was a non-significant reduction of the primary endpoint 
[14.1% vs. 16.2%; HR 0.88 (0.76–1.03)], while no difference in major bleeding 
rates was found [14.1% vs. 14.8%; HR = 0.95 (0.81–1.12)] [45]. The recommenda-
tions from the recent ESC guidelines for the selection of antithrombotic therapy in 
diabetic patients with an acute coronary syndromes in patients presenting without 
persistent ST-segment elevation, state that the therapy should not differ from those 
without diabetes [46].
Phase III trial data on the use of factor-Xa inhibition direct oral anticoagulants 
for treatment of ACS has emerged. The APPRAISE-2 (Apixaban for Prevention of 
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Acute Ischemic Events) resulted in early termination of the study, due to an increase 
in Thrombolysis in Myocardial Infarction (TIMI) major bleeding in apixaban 
5 mg bid (1.3%) compared with placebo (0.5%). There was no improvement in 
the composite of cardiovascular death, MI, or ischemic stroke with apixaban 
compared with placebo. Similarly, the ATLAS ACS 2-TIMI 51 (Anti Xa Therapy to 
Lower Cardiovascular Events in Addition to ASA with or without Thienopyridine 
Therapy in Subjects with Acute Coronary Syndrome—Thrombolysis in Myocardial 
Infarction) study had a significant increase in major bleeding with their respective 
Factor Xa inhibitors compared with dual antiplatelet therapy. It was noted however, 
in the primary analysis of the combined dosing arms, rivaroxaban (combined dose 
arms) reduced the composite of cardiovascular death, MI, or stroke compared with 
placebo (8.9% versus 10.7%, respectively). In a secondary analysis of the efficacy 
and safety of rivaroxaban (2.5 or 5 mg bid) compared with placebo in a pooled 
subset of ACS patients from the ATLAS ACS-TIMI 46 (phase II) and ATLAS ACS 
2-TIMI 51 (phase III) trials [47] showed that the addition of rivaroxaban to aspirin 
reduced a composite of cardiovascular death, myocardial infarction, and stroke 
versus aspirin alone, primarily by a reduction in the risk of myocardial infarction. 
However, the combined rivaroxaban dose groups were associated with higher 
rates of non-CABG TIMI major bleeding. The use of these strategies specifically in 
diabetic patients remains under investigation. In the stable cardiovascular disease 
setting, the Cardiovascular OutcoMes for People using Anticoagulation StrategieS 
(COMPASS) trial [48] investigated very low-dose rivaroxaban (2.5 mg b.i.d.) in 
combination with aspirin vs. aspirin alone or rivaroxaban 5 mg b.i.d. alone. Those 
assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular 
outcomes and more major bleeding events than those assigned to aspirin alone. 
Greater absolute risk reductions were seen in high-risk patients, including those 
with diabetes.
3. Percutaneous revascularisation in diabetic patients
Since its inception, the use of percutaneous transluminal balloon angioplasty 
(BA) to treat coronary stenosis, diabetics have shown less favourable long-term 
clinical outcomes, compared to non-diabetics. Diabetes mellitus has been identified 
as an independent predictor of restenosis. In fact, the restenosis rate following BA 
in diabetics ranges between 35% and 71%, which is much higher than seen in the 
general population (30–35%) [49]. In addition, the pattern of restenosis is more 
severe, as these patients typically show more proliferative and occlusive types of 
restenosis. The main contributor to the restenosis process following plain BA is 
negative remodelling (i.e., vessel shrinkage) [50] that accounts for 73% of lumen 
reduction after balloon angioplasty, while plaque burden contributes 27% [51].
Coronary stenting was able to reduce the occurrence of restenosis, not only 
in general population but also in diabetic patients [52]. Two pivotal randomised 
controlled trials demonstrated the beneficial effects of stenting as compared to BA, 
the STRESS and the BENESTENT trials [53, 54]. The analysis of diabetic patients 
in these two trials revealed a significant reduction in restenosis rate (STRESS: stent 
32%, balloon 42%; p = 0.046; BENESTENT: stent 22%, balloon 42%; p = 0.02) and 
clinical outcomes improvement at 6 months and at 4 years follow-up (including 
cardiac death, non-fatal MI and the need for repeat revascularization) [55]. Despite 
these results, restenosis rate remained higher in diabetics compared to non-dia-
betics. In a meta-analysis [56] of 16 studies, after stent implantation angiographic 
restenosis (defined as ≥50% diameter stenosis at follow-up) occurred in 550 of 2672 
(20.6%) of non-diabetics as compared to 130 of 418 (31.1%) of diabetic patients 
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(p < 0.001). The authors identified, among other factors, insulin treatment in type 
2 diabetes, a marker of disease duration and severity, as an independent predictor 
of restenosis. The prevailing mechanism of restenosis after stenting is accelerated 
intimal hyperplasia which is especially exaggerated in diabetic patients [57]. Thus, 
the development of drug-eluting stent (DES) to tackle this mechanism of restenosis 
directly was a revolutionary development in this field. In this regard, the subgroup 
analysis of the two pivotal randomised trial, which evaluated the efficacy of first 
generation DES (Cypher® stent; Cordis, Johnson & Johnson, Warren, NJ, USA and 
Taxus® stent; Boston Scientific, Natick, MA, USA) showed positive results in terms 
of restenosis rates and in MACE [58, 59].
In the SIRIUS trial (Sirolimus-coated Bx Velocity balloon-expandable stent 
in the treatment of patients with de novo coronary artery lesions) [60] a total of 
1058 patients were randomised to either SES or BMS for the treatment of de novo 
coronary stenosis. The primary endpoint was target vessel failure (cardiac death, 
myocardial infarction and target vessel revascularisation [TVR]) at 9-month 
follow-up. The diabetes subgroup analysis of the SIRIUS trial included 279 patients, 
131 receiving SES and 148 receiving BMS [61]. In this subgroup of patients, SES 
implantation demonstrated favourable results with significant reductions in reste-
nosis rates (in-lesion 50% for BMS vs. 17% for SES), and in MACE (25% for BMS 
vs. 9.2% for SES). The TAXUS IV trial [62] enrolled 1326 patients that were ran-
domised to PES or BMS for the treatment of de novo coronary stenosis. The primary 
endpoint was ischaemia driven TVR and the incidence of cardiac death, and MI at 
one year. Overall, the PES group showed a significant reduction in the occurrence 
of the primary endpoint (TVR 7.4% vs. 20.9%, p = 0.0008). The study included 
155 diabetic patients (32% of the total population) and 33% of the diabetics were 
insulin-dependent DM. In this subgroup, the use of PES significantly reduced the 
risk of binary restenosis (70% reduction of in-segment restenosis). This reduction 
was also observed in insulin-dependent DM subjects (42.9% for BMS vs. 7.7% for 
PES, p = 0.007).
The DIABETES (Diabetes and Sirolimus-Eluting Stent) trial [63] was the first 
randomised multicentre controlled trial specifically designed to assess the efficacy 
of SES vs. BMS in diabetics. This study included 160 diabetic patients, 80 of whom 
received BMS, while 80 were treated with SES. Late lumen loss assessed by QCA 
at 9-month follow-up was the primary endpoint. The SES treated group showed a 
significant reduction of late lumen loss (relative reduction 87%). The study con-
sidered a sub-randomisation, according to the type of anti-diabetic treatment and 
the SES benefit was independent from diabetic status. This benefit was maintained 
up to 5-year follow-up [64]. Subsequently, 3 other randomised trials also designed 
for diabetic patients (SCORPIUS [65, 66], DESSERT [67] and DECODE [68]) have 
corroborated the same positive results of SES in reducing neointimal proliferation 
to mid and long-term. A meta-analysis of all available data in diabetics treated with 
PCI [69] demonstrated the benefit of DES in terms of restenosis and target lesion 
revascularisation.
Finally, other studies compared both DES in terms of efficacy (Table 1). The 
SIRTAX (SIRolimus versus pacliTAXel-eluting stents) trial [70] and the ISAR 
(In-Stent Angiographic Restenosis)-DIABETES trial [71] showed that SES in dia-
betics had lower MACE and lower late lumen loss compared with PES. The efficacy 
of new generation DES has also been evaluated. The everolimus-eluting stent (EES) 
has been tested against PES in the SPIRIT IV and V trial. In the subgroup analyses 
of the SPIRIT IV [72] EES compared with PES showed no difference in target lesion 
failure (6.4% vs. 6.9%, respectively, p = 0.80) or any of its components was pres-
ent among diabetic patients, regardless of insulin use. In contrast, in the SPIRIT V 
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Randomised controlled trials comparing drug-eluting stent vs. drug-eluting stents in diabetic patients.
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Diabetic Study Everolimus-eluting stent was superior to PES for in-stent late loss 
at 9 months, however, clinical endpoints were similar between the two groups [73]. 
Interestingly no stent thromboses (Academic Research Consortium definite and 
probable) were seen at 1 year with EES, compared with 2 of 104 (2%) with PES 
(P = 0.11). The efficacy of the zotarolimus-eluting stent (ZES) has been assessed 
in the Endeavour IV trial against PES [74] and the Resolute™ [75] stent a new 
generation ZES against EES. In these studies, ZES was comparable with PES and 
non-inferior to EES. Finally, the biolimus-eluting stent (BES) has been compared to 
SES in the LEADERS all-comer trial. BES appeared to be non-inferior to SES with 
regard to the primary endpoint in the subgroup of diabetics [76].
The effectiveness of different DES platforms has been addressed in the Swedish 
Angiography and Angioplasty Registry (SCAAR) [77]. Data on restenosis from 
2004 and 2008 was collected. Four DES types qualified for inclusion. In total, 
35,478 DES were implanted at 22,962 procedures in 19,004 patients and 1807 
restenosis events were reported over a mean 29-month follow-up. In the entire 
study population, the restenosis rate per stent was 3.5% after 1 year and 4.9% after 
2 years. The adjusted risk of restenosis was higher in patients with DM, compared 
to patients without DM (relative risk [RR]: 1.23, 95% confidence interval [CI]: 1.10 
to 1.37). In patients with DM, restenosis was twice as frequent with the ZES stent 
compared with that in SES and PES types.
Another important aspect in the use of DES is the safety, especially in diabetic 
patients. Safety of DES mainly refers to the incidence of ST, MI or death during 
follow-up. Diabetes has been identified as an independent predictor of ST in many 
registries with the use of first-generation DES (SES and PES) [17, 78]. In a large 
multicentric registry 66 of more than 15,000 patients treated with SES, the overall 
incidence of stent thrombosis at 1 year was 0.87% and the most potent independent 
predictor of thrombosis was the insulin-dependent DM [78]. Diabetic patients, 
as mentioned previously, exhibit specific pathophysiological factors as well as 
unfavourable angiographic parameters, which confers an especially high risk of 
thrombosis.
A Swedish Registry (SCAAR) compared diabetic patients treated with DES to 
those treated with BMS. The median follow-up was 2.5 years. This study included 
4754 patients who received at least one DES and 4956 patients that received only 
bare metal stents (BMS) at the index procedure. The study showed that restenosis 
was halved by DES in diabetic patients with stable or unstable coronary disease, 
compared with BMS [RR, 0.50 (95% CI, 0.35–0.70)] and was associated with a 
higher adjusted RR of MI, [RR 5.03 (95% CI, 4.25–5.97)] [79].Similar results were 
observed in a meta-analysis of individual patient data from four randomised trials 
reporting on the use of SES in diabetics [80]. This meta-analysis included 583 
patients (SES vs. BMS; median follow-up of 4.2 years). There was a significant 
reduction in the overall hazard of MACE (hazard ratio, [HR] 0.48, 95% confidence 
interval [CI] 0.36–0.63, P < 0.001) with SES. The overall hazard of death (HR 0.91, 
95% CI 0.59–1.41, P = 0.68), as well as death or MI (HR 0.77, 95% CI 0.54–1.09, 
P = 0.14), was not significantly different between the groups. No significant dif-
ferences were observed regarding ST (HR 0.50, 95% CI 0.15–1.69, P = 0.26) [80].
Reassuring data also comes from the Massachusetts Data Analysis Registry that 
included 6008 diabetics treated between April 2003 and September 2004. After 
propensity score-matched risk analysis, the use of DES was associated with a 
significantly lower rate of death, MI and TVR [52].
New generation EES stent showed a safety benefit as compared to PES in the 
Spirit V- diabetic randomised trial at 1 year; the composite of death and MI was 
reduced by EES (9.6% vs. 3.7%; p = 0.04) as well as the thrombosis rate (1.9% vs. 
0%; p = ns) [73].
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Data concerning safety of BES in diabetics comes from a sub-study from the 
LEADERS trial. Among insulin-dependent diabetics, the rate of all-cause death and 
cardiac death was 0% after BES implantation, compared to 9.1% and 6.5% respec-
tively, after SES implantation at 12 months follow-up (p < 0.01) [76].
Finally, the Resolute™ stent showed a higher incidence of definite ST at 1-year 
follow-up, compared to EES (1.2% vs. 0.3%; <0.01) in the all-comer RESOLUTE 
trial [81].
4. Multivessel disease in diabetics
Based on the current evidence, coronary artery bypass graft (CABG) is the 
treatment of choice for diabetic patients with multivessel disease [82]. However, 
since the inception of percutaneous coronary intervention, numerous trials have 
been designed to evaluate the efficacy of PCI versus CABG in patients with multi-
vessel disease. In the following section, we will discuss the various trials that have 
compared surgical revascularisation to percutaneous intervention, beginning with 
balloon angioplasty and continuing to the modern DES era.
4.1 Trials comparing CABG and BA
Four trials designed to compare the efficacy of CABG versus BA have reported 
data on the subgroup of patients with diabetes mellitus: the EAST study, the BARI 
study, the CABRI trial and the RITA trial (Table 2) [83–86]. The only study that 
showed a significant benefit in survival of diabetic patients treated with CABG 
compared with BA, was the BARI trial. On the basis of these results, a clinical alert 
to US physicians from the National Heart, Lung, and Blood Institute, was published 
in Circulation 1995 and concluded that CABG should be the preferred treatment for 
patients with diabetes on drug or insulin therapy, who have multivessel coronary 











BARI [80] Angina or severe 
ischemia, CAD amenable 







7.8 PTCA 45.5% vs. 
CABG 57.8%, 
p = 0.025).
EAST [79] MV CAD, no previous 
Rev; no LMS stenosis, no 








CABRI [82] Age ≤76, MV CAD + 
clinical evident ischemia; 
no previous Rev, LMS 







RITA [81] >50-70% coronary 
stenosis SA or UA, de 
novo single or MV CAD 













4.2 Trials comparing CABG versus PCI with bare metal stents
There are four randomised trial that compared the outcomes from bypass 
surgery versus coronary stenting in patients with multivessel disease: the ARTS, 
the AWESOME trial, the SOS and the ERACI II trial. Only the first two trials 
analysed the diabetic subgroup separately, and neither showed any survival benefit. 
The ARTS (Arterial Revascularisation Therapy Study) trial reported a reduced 
event-free survival at 1 year in diabetics treated with stenting, as compared with 
those treated with CABG (63.4% vs. 84.4%, p = 0.001) [87]. This difference was 
largely due to a significant increase in repeat revascularisation in the stent group. 
Of note, the rate of complete revascularisation in patients who underwent PCI was 
only (70.5%) compared with those who had CABG (84.1%). Conversely, the rate 
of death and MI in diabetic were similar between groups (6.7% vs. 3.1%, p = 0.29 
and 6.3% vs. 3.1%, p = 0.29, respectively). In addition, a trend towards an increase 
in the rate of cerebrovascular events was observed in the CABG group (1.8% vs. 
6.3%, p = 0.009). At five years, there was no significant difference in mortality 
between the two groups. However, it was noted, that the rate of myocardial infarc-
tion was highest in the BMS arm, compared with CABG arm (11.0% vs. 5.2%). The 
AWESOME trial (Angina With Extremely Serious Operative Mortality Evaluation 
Trial) randomised 454 patients with multivessel disease to either CABG or stent-
ing. Among diabetics, the respective CABG and PCI 36-month survival rates were 
comparable (72% for CABG vs. 81% for PCI) [88]. A collaborative analysis of data 
from ten randomised trials to compare the effectiveness of CABG with PCI (six tri-
als used balloon angioplasty and four trials used with bare-metal stents), in patients 
with multivessel disease, showed that patients with diabetes (CABG, n = 615; PCI, 
n = 618), mortality was substantially lower in the CABG group than in the PCI 
group (HR 0.70, 0.56–0.87) [89].
In summary, despite these trials demonstrating a reduced need for subsequent 
revascularization following PCI with stents as compared to BA, the need for repeat 
revascularization remained significantly higher when compared to CABG in the 
diabetic population with multivessel disease. Moreover, the rate of myocardial 
infarction in diabetics was higher at long-term follow-up with the use of stents as 
compared to CABG. Thus, in the BMS era, revascularisation of diabetic patients 
with multivessel disease, CABG remained the first option of revascularization in 
patients suitable for surgery.
4.3 Trials comparing CABG and DES
The data available in the current era of DES comes from a combination of 
registry data, subgroup analysis from two randomised trials (the SYNTAX trial 
and the EXCEL trial) and two randomised trial performed specifically in diabetics 
patients. Beginning with the registry data, there are two multicentre registries that 
report data for diabetic patients treated with DES: the ERACI-3 and the ARTS 2 
registries. Both registries compared a current cohort of patients with multivessel 
disease treated with drug-eluting stents with the historical cohort of patients from 
ERACI 2 and ARTS 1 trial respectively; treated with either CABG or conventional 
BM stenting. The ARTS 2 registry was a single arm trial that included 607 patients 
with multivessel disease treated with SES. The ARTS I and II studies included 367 
diabetic patients (SES: 159, CABG: 96, and BMS: 112); at the 5-year follow up, the 
rate of major adverse cardiovascular and cerebrovascular events were significantly 
higher in patients treated with BMS (BMS 53.6% vs. CABG 23.4% vs. SES 40.5%; 
p < 0.01 for SES vs. BMS and SES vs. CABG). There was no significant difference 
in mortality among all 3 groups. There was an advantage of CABG over SES in 
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reducing repeat revascularisation procedures; interestingly revascularisation rate 
of patients treated with SES at 5 years approached that of patients treated with 
BMS although remained significantly lower. This “catch-up” phenomenon was not 
 apparent in the non-diabetic population [90].
In the diabetic subgroup of ERACI-3 registry [91], MACCE rates at 3 years 
were 36.2% in the DES arm, 43.6% in the BMS arm, and 30.8% in the CABG group 
(p = 0.49). Of the components of MACCE, TVR was the only one that differed 
significantly across the three groups: drug-eluting stent (21.3%), bare metal stent 
(38.5%), and CABG (15.4%); p = 0.048. There was a non-significant trend towards 
more death and non-fatal MI among diabetics treated with DES (19.1%), than in the 
bare metal stent (12.8%) or CABG (15.4%) cohort of ERACI-2. Sub-acute late-stent 
thrombosis occurred more frequently in DES-treated patients, compared with BMS 
patients (P = 0.008).
Another registry [92] compared DES implantation with off-pump CABG. This 
study addresses the effect of DES versus off-pump CABG, on 1-year outcome of 
diabetic patients with multivessel disease and critical stenosis, involving the proxi-
mal left anterior descending coronary artery, who underwent elective myocardial 
revascularisation. Following propensity score analysis, adjusting for baseline dif-
ferences between the 2 cohorts, DES increased the risk of 12-month MACCE (HR 
1.88, 95% CI, p = 0.020). This was due to the higher rate for repeat revascularisation 
in the DES group (19% vs. 5%, HR 2.05, 95% CI, p = 0.001). In contrast, there 
was no difference in the rate of the composite endpoints of death, MI, and stroke 
(DES group 13%, CABG group 12%; adjusted analysis, HR 0.80, 95% CI, p = 0.40). 
On the other hand, the New York registry [93] showed a trend towards improved 
outcomes in diabetic patients treated with CABG (n = 3256), compared with DES 
(n = 2844) (or for death or MI at 18 months 0.84, 95% CI 0.69–1.01; p = 0.07).
The SYNTAX (Synergy between percutaneous coronary intervention with 
TAXUS and cardiac surgery) trial randomly allocated 1800 patients with left 
main and/or 3-vessel coronary artery disease to PES implantation or CABG. In the 
subgroup of patients with DM (n = 452), MACCE rate was significantly higher at 
1 year with PES than with CABG (26.0% vs. 14.2%; RR 1.83 [1.22–2.73]; p = 0.003), 
at the expense of higher repeat revascularisation with PES (6.4% vs. 20.3%; RR 3.18 
[1.77–5.71]; p < 0.001). Safety endpoint (death, stroke or MI), as well as symptom-
atic graft occlusion or stent thrombosis rates were comparable between treatment 
arms. Of note, in patients with SYNTAX score > 33, death rate was significantly 
higher with PES (13.5% vs. 4.1%; p = 0.04) [94].
There are two randomised trials comparing DES and CABG in patients with 
diabetes. The CARDIA trial (Coronary Artery Revascularisation in Diabetes) 
[95] is a non-inferiority trial, comparing optimal PCI with modern CABG, as 
a revascularisation strategy for patients with diabetes who have multivessel or 
complex single-vessel coronary disease. The 1-year results of the CARDIA trial did 
not demonstrate the noninferiority of PCI versus CABG for revascularisation of 
diabetic patients. At 1 year, the primary endpoint (composite of death, non-fatal 
MI and non-fatal stroke) was comparable between arms (10.5% in CABG vs. 13.0% 
in PCI arm; p = 0.39), only further revascularisation was significantly higher in the 
PCI arm (2% vs. 11.8%; p < 0.001). Although this study was the first randomised 
trial that compared the two revascularisation strategies in diabetic patients, it was 
underpowered for the primary composite outcome. Therefore, further information 
on optimal strategies for coronary revascularisation in diabetic patients is needed.
The FREEDOM trial (Future Revascularisation Evaluation in Patients with 
Diabetes Mellitus: Optimal Management of Multivessel Disease) is a randomised 
trial, in which patients with diabetes and multivessel disease were randomly 
assigned to undergo multivessel PCI using DES versus bypass surgery and followed 
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for up to 5 years. At 5 years follow-up, the primary outcome: a composite of death 
from any cause, nonfatal myocardial infarction, and nonfatal stroke occurred more 
frequently in the PCI group, compared with the CABG group (26.6% vs. 18.7%; 
p = 0.005). The benefit of CABG was driven by differences in rates of both myocar-
dial infarction (P < 0.001) and death from any cause (P = 0.049). Cardiac death was 
not significant (p = 0.12). Stroke was more frequent in the CABG group than in the 
PCI group (2.4% vs. 5.2%; p = 0.03) [96].
The BARI 2 Diabetes (BARI 2D) [97] is a randomised, open, controlled, mul-
ticentre trial that compared optimal medical management with prompt revascu-
larisation (PCI or CABG) in patients with type 2 DM and stable coronary disease. 
The primary endpoint was death from any cause. At 5-year follow-up, survival 
rate was comparable between groups (88%) with no difference in MACE or death. 
Patients treated with CABG showed much greater atherosclerotic burden and more 
lesions than the PCI stratum. Prompt revascularisation significantly reduced the 
MACE rate in those patients treated with CABG, largely because of a reduction 
in MI events, but not among those selected to undergo PCI as compared to opti-
mal medical treatment. However, up to 42% of the patients allocated to optimal 
 medical therapy required coronary revascularisation with PCI during the 5 years of 
follow-up [97].
A recent meta-analysis of 11 RCTs [98], involved 11,518 patients allocated to PCI 
or CABG. The 5-year all-cause mortality was 11.2% after PCI and 9.2% after CABG 
(HR 1.20, 95% CI 1.061.37; P = 0.0038). Among patients with DM, mortality rates 
were 15.7% in PCI and 10.1% in CABG (HR 1.44, 95% CI 1.201.74; P = 0.0001). 
Conversely, this difference was not found among non-diabetic patients.
There have been a number of studies comparing outcomes of CABG and PCI 
that involved the use of newer-generation DES. A large meta-analysis including 
8095 patients with DM showed a significant reduction in MI, stent thrombosis, and 
MACE, with newer-generation everolimus-eluting stents, compared to first genera-
tion DES [99]. Data from the Randomised Comparison of Coronary Artery Bypass 
Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients 
with Multivessel Coronary Artery Disease (BEST) study [100], showed that the 
outcomes were poorer in the PCI group, with the rate of the primary outcome of 
death, MI, or TVR at two years significantly higher (19.2 vs. 9.1%; P = 0.007). In 
a subgroup analysis of 505 patients with DM, in the Evaluation of XIENCE versus 
Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularisation 
(EXCEL) trial [101], the investigators reported the rate of the primary outcome of 
death, MI or stroke at three years occurred in 21.2% of patients in the PCI arm and 
19.4% in the CABG arm (HR 1.04, 95% CI 0.70–1.55). In conclusion, is clear that 
we are yet to determine whether the newer generation DES will begin to narrow the 
divide favouring CABG for patients with DM and multivessel disease, and addition-
ally, that further dedicated randomised control trials are needed.
5.  The importance of atherosclerosis progression in the long-term 
outcome after myocardial revascularisation
Atherosclerotic coronary artery disease is a chronic condition that is not limited 
by revascularisation. The short and long-term outcomes in patients undergoing 
both percutaneous and surgical revascularisation, are not only determined by stent 
or graft failure, but also by atherosclerotic disease progression in other territories. 
A paucity of data exists regarding the impact of atherosclerosis progression on 
the outcome of patients after revascularisation, and this is particularly evident in 
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patients with diabetes. The current data regarding atherosclerosis progression after 
percutaneous revascularisation is limited. One of the studies that address this issue 
was the study conducted by Cutlip et al. [102] This study included 1228 patients 
treated with BMS. The cumulative incidence of restenosis events, non-restenosis 
events, and the overall composite end point up to 5 years was evaluated. In this 
study, it was demonstrated that the events relating to restenosis increased during 
the first year, however there was a virtual absence of restenosis thereafter. On the 
other hand, the rate of non-restenosis events increased during the first year, in 
parallel to the restenosis events but continued to increase out to 5 years. The two 
factors that were independently associated with an increased risk of restenosis and 
non-restenosis events were diabetes and multivessel disease.
Zellweger et al. [103] studied the importance of 5-year coronary disease pro-
gression after successful DES stenting. This is a sub-study of the Basket trial and 
involved 428 consecutive patients randomised to drug-eluting versus bare-metal 
stents, with successful stenting documented by freedom from symptoms/events 
and non-ischaemic perfusion defects (PDs) after 6 months. Rest and stress scintig-
raphy scans were repeated after 60 months. Late events and new perfusion defects 
in areas remote from stented vessels were recorded. At 5 years follow-up, 37.1% of 
all events were due to remote MI, or remote repeat revascularisation. In addition, 
asymptomatic remote perfusion defect accounted for 37.5%. There is also informa-
tion about the impact of atherosclerosis progression derived from large randomised 
trials comparing DES vs. BMS. In the 5-years of the SIRIUS (Sirolimus-Eluting Stent 
in De-Novo Native Coronary Lesions) trial, 28% of MI were located in non-target 
vessels. In addition, 64% in the SES group and the 42.% in the BMS group of all 
target vessel revascularisation were non performed in the target lesion [104]. In 
the 5-year TAXUS IV Treatment of De Novo Coronary Disease Using a Single 
Paclitaxel-Eluting Stent trial: 45% of all revascularisation in the PES group were due 
to non-target lesion TVR [105].
The progression of atherosclerosis in diabetics has been specifically assessed 
by Rozeman et al. [106]. This study included 248 patients (55 diabetics/193 non 
diabetics) and evaluated the percentage of arteries with new narrowing’s at follow-
up angiography following angioplasty. The authors observed that the percentage of 
new narrowing was more often in diabetic patients compared to non-diabetics (14.8 
vs. 9.4%; p = 0.03) and particularly in the arteries previously treated with angio-
plasty (13.6 vs. 8.5; p = 0.01). The 5 year follow-up of the DIABETES (DIABETes 
and sirolimus-Eluting Stent) trial, showed that the need for new revascularisation 
in the SES group was due equally to restenosis and progression of atherosclerosis 
in other territories [64]. On the other hand, surgical revascularisation also have 
disease progression [107]. It has been described that the progression is primarily in 
the proximal segment before the anastomosis (74%) and the majority was proximal 
coronary occlusion (78%). This pattern of atherosclerosis progression may be 
mostly asymptomatic in patients with a patent graft and prevents future events due 
to plaque rupture in the proximal segment of the artery.
This data suggested that the clinical implication of atherosclerosis progression 
is different in the two-revascularisation strategies and negatively affects patients 
treated percutaneously, particularly after the first year of clinical follow-up. This 
has to be taken into account, when comparing long term results of stent implanta-
tion versus CABG in patients with multivessel disease. Improvements in both the 
stent platforms and the adoption of new drug coatings have improved the outcome 
of patients treated with PCI. However, it is critical, particularly in the diabetic pop-
ulation to improve the secondary prevention strategies to decrease the  occurrence 
of events due to atherosclerosis progression.
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6. Current recommendations for revascularisation in diabetics
Contemporary guidelines place emphasis on the long-term survival benefit 
conferred by CABG, for treatment of diabetics with multivessel disease. A clini-
cian’s judgement on the revascularisation strategy remains an important factor. 
Although PCI with DES has narrowed the gap with surgery, following the results of 
the FREEDOM trial in CABG-eligible diabetic patients multivessel disease, CABG 
remains the gold standard treatment [16, 96] (Tables 3 and 4).
Recommendations Class Level
It is recommended that the same revascularisation techniques are implemented(e.g. the 
use of DES and the radial approach for PCI, and the use of the left internal mammary 
artery as the graft for CABG) in patients with and without DM.
I A
It is recommended that renal function should be checked if patients are taking 
metformin immediately before angiography and that metformin should be withheld if 
renal function deteriorates.
I C
Optimal medical therapy should be considered to be the preferred treatment in patients 
with CCS and DM unless there are uncontrolled ischaemic symptoms, large areas of 
ischaemia or significant left main or proximal LAD lesions.
IIa B
CABG = coronary artery bypass graft; CCS = chronic coronary syndromes; DES = drug-eluting stent; DM = diabetes 
mellitus; EACTS = European Association for Cardio-Thoracic Surgery; ESC = European Society of Cardiology; 
LAD = left anterior descending coronary artery; PCI = percutaneous coronary intervention.
Table 4. 
Recommendations for coronary revascularisation in patients with diabetes. Adapted from 2018 ESC/EACTS 
Guidelines on myocardial revascularization.
Recommendations according to the extent of CAD CABG PCI
CLASS LEVEL CLASS LEVEL
One vessel CAD
Without proximal LAD stenosis IIb C I C
With proximal LAD stenosis I A I A
Two vessel CAD
Without proximal LAD stenosis IIb C I C
With proximal LAD stenosis I B I C
Three vessel CAD
With low disease complexity (SYNTAX score 0-22) I A IIb A
With intermediate or high disease complexity 
(SYNTAX score >22)
I A III A
Left main CAD
With low disease complexity (SYNTAX score 0-22) I A I A
With intermediate disease complexity (SYNTAX score 
23-32)
I A IIa A
With high disease complexity (SYNTAX score ≥ 33) I A III B
CABG = coronary artery bypass graft; CAD = coronary artery disease; DM = diabetes mellitus; LAD = left anterior 
descending coronary artery; PCI = percutaneous coronary intervention; SYNTAX = Synergy between Percutaneous 
Coronary Intervention with TAXUS and Cardiac Surgery.
Table 3. 
Recommendations for the type of revascularization in patients with diabetes with stable coronary artery 
disease, suitable coronary anatomy for both procedures, and low predicted surgical mortality. Adapted from 
2018 ESC/EACTS Guidelines on myocardial revascularization.
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7. Conclusions
Diabetic patients are a very high-risk population. The unfavourable anatomy 
and the prothrombotic state contribute to the poor acute and midterm outcome 
following percutaneous revascularisations. With the advent of DES, improved stent 
designs and antiplatelet drugs; the rate of TLR and MACE has also improved in dia-
betic patients; however, it remains higher in comparison to non-diabetic patients. 
We have underestimated the impact of atherosclerosis progression in the appear-
ance of late events after PCI, particularly in patients with diabetes. Whilst it is 
clearly evident that both aggressive secondary prevention and lifestyle modification 
are mandatory to alter the natural history of CAD in this group, the gold standard 
for diabetic patient with complex multivessel disease is surgical revascularisation.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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